NT 219

Drug Profile

NT 219

Alternative Names: NT219

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer TyrNovo
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Neurodegenerative disorders

Most Recent Events

  • 11 May 2018 TyrNovo has patent protection for NT 219 in Israel
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Israel
  • 01 Nov 2017 Kitov Pharmaceuticals plans a phase I/II trial for NT 219 in Pancreatic cancer (Late stage disease; Combination therapy) in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top